dihexa bbb permeable A new player in blood-brain-barrier integrity AngIV-Analog Dihexa Rescues Cognitive Impairment

Many patients notice improvements in pain, inflammation, and mobility within 1-3 weeks of starting BPC/TB-5 therapy

Preclinical models report tendon, ligament, muscle, and gut healing benefits, but human evidence remains limited to a handful of small open-label pilot studies

For 5-amino-1MQ specifically: Preclinical studies have not prominently described heart rate elevation as a dominant signal The mechanism (NNMT inhibition, NAD+ preservation) does not have the same direct cardiac implications as nuclear receptor agonism Human cardiovascular data at clinically relevant exposures are limited For physicians, the current evidence base does not support a major cardiovascular safety flag, but the limited human dataset means confident statements are premature

Do not throw used needles in the regular trash